Clinical Trial

Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

Study acronym: AQUARELLE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to study the efficacy and safety of BCD-132 (divozilimab) in subjects with neuromyelitis optica spectrum disorders (NMOSD).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-07; most recent amendment 2024-11-06.
Status change: Recruiting → Active, Not Recruiting 2024-11-06
Trial Details
NCT Number NCT05730699
Lead Sponsor Biocad
Conditions Neuromyelitis Optica Spectrum Disorders
Enrollment 105 participants
Start Date 2022-12-12
Primary Completion 2025-01 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2024-11-07